New Data on Nabriva's Pneumonia Drug Sends Share Price Soaring

Nabriva Therapeutics plc (NASDAQ:NBRV) saw a major boost to its stock on Monday (September 18) following the announcement of top-line results from its trial of a pneumonia drug.
The drug, callled Lefamulin was tested in patients currently being treated for community-acquired bacterial pneumonia (CABP).  Lefamulin met the endpoints set in place by both leading regulatory agencies: the US Food and Drug Administration and the European Medicines Agency (EMA). In both cases, the drug surpassed the treatment offered by current options with or without other joint drugs.
At market close on Monday Nabriva’s stock enjoyed a 29.30 percent growth over the one-day trading period. Year-to-date, the company  Nabriva has seen a 19.51 percent decline, although this newfound upside for their stock should prove a relief for long-term investors.

‘Strong potential’ for Nabriva’s pneumonia drug

Dr. Colin Broom, chief executive officer of Nabriva Therapeutics, said the data from the first of two phase 3 sets of the LEAP 1 trial, showed “strong potential” for the company’s drug to treat adults with CABP.
“Due to lefamulin’s flexible dosing and targeted spectrum of activity against the pathogens most commonly associated with CABP… we believe that lefamulin is well suited to be a first-line empiric monotherapy,” Dr. Broom said on the company’s announcement.
On the analyst data site TipRanks, Nabricva held a price target of $16.33 for the next 12 months, alongside a “Strong Buy” recommendation based on the studies of 3 analysts.
According to a report from Reuters, if Nabriva’s drug surpasses the clearance stage from the FDA, it would become the first “pleuromutilin to be approved for oral or intravenous use.”
If Nabriva’s lefamulin manages to get the U.S. Food and Drug administration’s clearance after its second late-stage study, it would be the first pleuromutilin to be approved for oral or intravenous use.

Medical expert weighs in regarding data

Dr. Thomas M. File Jr., chair of the Infectious Disease Section at the Northeast Ohio Medical University and chair of the Infectious Disease Division with Summa Health, called the results “promising” in combating a life-threatening disease which its current treatments see limitations “often associated with resistance or safety.”
These positive topline results evaluating the efficacy and safety of lefamulin in patients with community-acquired bacterial pneumonia are promising.”
The company said it would continue to update shareholders on new information at upcoming conferences available.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.